Panelists discuss how the evolving landscape of targeted therapies for PIK3CA-mutated HR+ HER2- breast cancer, including the approval of inavolisib and the growing importance of biomarker testing, is reshaping treatment strategies, patient care, and adverse event management.
This cross-sectional study uses a large natural language processing model to examine unmet medical and social needs based on cancer-related fundraising stories in the US.
An abstract is unavailable.
A panel of experts on multiple myeloma review patient cases and discuss the treatment of patients with relapsed/refractory disease, highlighting sequencing strategies and clinical trials…
Luveltamab tazevibulin produced responses in patients with platinum-resistant ovarian cancer.
Oncogene – A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancer
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, comments on the recent developments in the treatment of acute myeloid leukemia (AML), sharing…
With the Oncology Brothers, Uma Borate, MD, discusses how the combination of venetoclax with an IDH1 inhibitor and 7+3 chemotherapy leads to higher remission rates…
Tamoxifen reduced the risk of invasive ipsilateral breast recurrence in patients with good-risk ductal carcinoma in situ.
Our findings suggest that NF1 individuals may have a higher risk for developing melanomas and tend to have thicker melanomas and worse survival compared to…
Cancer touches all of us. Our mission – to contribute to the prevention and cure of cancer – depends on your support. There are many…
